WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522518

CAS#: 162203-65-8

Description: JTP-4819 is a potent and selective prolyl endopeptidase (PEP) inhibitor with potential for treating Alzheimer's disease. At nanomolar concentration, JTP-4819 inhibited the degradation of substance P, arginine-vasopressin, and thyrotropin-releasing hormone by PEP in supernatants of the rat cerebral cortex and hippocampus. Repeated administration of JTP-4819 reversed the aging-induced decrease in brain substance P-like and thyrotropin-releasing hormone-like immunoreactivity, suggesting that this drug may be able to improve the imbalance of peptidergic neuronal systems that develops with senescense by inhibiting PEP activity. JTP-4819 increased acetylcholine release from the frontal cortex and hippocampus, regions closely associated with memory, in both young and aged rats.

Chemical Structure

CAS# 162203-65-8

Theoretical Analysis

MedKoo Cat#: 522518
Name: JTP-4819
CAS#: 162203-65-8
Chemical Formula: C19H25N3O4
Exact Mass: 359.1845
Molecular Weight: 359.43
Elemental Analysis: C, 63.49; H, 7.01; N, 11.69; O, 17.81

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: JTP-4819; JTP 4819; JTP4819.

IUPAC/Chemical Name: (S)-N-benzyl-2-((S)-2-(2-hydroxyacetyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxamide


InChi Code: InChI=1S/C19H25N3O4/c23-13-17(24)15-8-4-10-21(15)18(25)16-9-5-11-22(16)19(26)20-12-14-6-2-1-3-7-14/h1-3,6-7,15-16,23H,4-5,8-13H2,(H,20,26)/t15-,16-/m0/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 359.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Jalkanen AJ, Leikas JV, Forsberg MM. Prolyl oligopeptidase inhibition decreases extracellular acetylcholine levels in rat hippocampus and prefrontal cortex. Neurosci Lett. 2014 Sep 5;579:110-3. doi: 10.1016/j.neulet.2014.07.026. Epub 2014 Jul 23. PubMed PMID: 25064702.

2: Jalkanen AJ, Piepponen TP, Hakkarainen JJ, De Meester I, Lambeir AM, Forsberg MM. The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum. Neurochem Int. 2012 Feb;60(3):301-9. doi: 10.1016/j.neuint.2011.12.010. Epub 2011 Dec 22. PubMed PMID: 22210165.

3: Jalkanen AJ, Hakkarainen JJ, Lehtonen M, Venäläinen T, Kääriäinen TM, Jarho E, Suhonen M, Forsberg MM. Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):443-51. doi: 10.1111/j.1742-7843.2011.00747.x. Epub 2011 Jul 28. PubMed PMID: 21707925.

4: Moreno-Baylach MJ, Felipo V, Männistö PT, García-Horsman JA. Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience. 2008 Oct 15;156(3):580-5. doi: 10.1016/j.neuroscience.2008.06.072. Epub 2008 Jul 25. PubMed PMID: 18718510.

5: Jalkanen AJ, Puttonen KA, Venäläinen JI, Sinervä V, Mannila A, Ruotsalainen S, Jarho EM, Wallén EA, Männistö PT. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol. 2007 Feb;100(2):132-8. PubMed PMID: 17244263.

6: Puttonen KA, Lehtonen S, Raasmaja A, Männistö PT. A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. Toxicol In Vitro. 2006 Dec;20(8):1446-54. Epub 2006 Jul 14. PubMed PMID: 16942854.

7: Collins PJ, McMahon G, O'Brien P, O'Connor B. Purification, identification and characterisation of seprase from bovine serum. Int J Biochem Cell Biol. 2004 Nov;36(11):2320-33. PubMed PMID: 15313476.

8: Venäläinen JI, Juvonen RO, Forsberg MM, Garcia-Horsman A, Poso A, Wallen EA, Gynther J, Männistö PT. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol. 2002 Aug 1;64(3):463-71. PubMed PMID: 12147298.

9: Wallén EA, Christiaans JA, Saario SM, Forsberg MM, Venäläinen JI, Paso HM, Männistö PT, Gynther J. 4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorg Med Chem. 2002 Jul;10(7):2199-206. PubMed PMID: 11983517.

10: Shinoda M, Miyazaki A, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav Brain Res. 1999 Feb 15;99(1):17-25. PubMed PMID: 10512568.

11: Toide K, Shinoda M, Miyazaki A. A novel prolyl endopeptidase inhibitor, JTP-4819--its behavioral and neurochemical properties for the treatment of Alzheimer's disease. Rev Neurosci. 1998;9(1):17-29. Review. PubMed PMID: 9683325.

12: Miyazaki A, Toide K, Sasaki Y, Ichitani Y, Iwasaki T. Effect of a prolyl endopeptidase inhibitor, JTP-4819, on radial maze performance in hippocampal-lesioned rats. Pharmacol Biochem Behav. 1998 Feb;59(2):361-8. PubMed PMID: 9476982.

13: Shinoda M, Toide K, Ohsawa I, Kohsaka S. Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells. Biochem Biophys Res Commun. 1997 Jun 27;235(3):641-5. PubMed PMID: 9207212.

14: Umemura K, Kondo K, Ikeda Y, Kobayashi T, Urata Y, Nakashima M. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers. Br J Clin Pharmacol. 1997 Jun;43(6):613-8. PubMed PMID: 9205821; PubMed Central PMCID: PMC2042786.

15: Toide K, Shinoda M, Fujiwara T, Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol Biochem Behav. 1997 Mar;56(3):427-34. PubMed PMID: 9077579.

16: Toide K, Shinoda M, Iwamoto Y, Fujiwara T, Okamiya K, Uemura A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51. PubMed PMID: 9062674.

17: Shinoda M, Matsuo A, Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur J Pharmacol. 1996 Jun 3;305(1-3):31-8. PubMed PMID: 8813528.

18: Toide K, Fujiwara T, Iwamoto Y, Shinoda M, Okamiya K, Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1996 Feb;353(3):355-62. PubMed PMID: 8692293.

19: Shinoda M, Okamiya K, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on thyrotropin-releasing hormone-like immunoreactivity in the cerebral cortex and hippocampus of aged rats. Jpn J Pharmacol. 1995 Nov;69(3):273-6. PubMed PMID: 8699636.

20: Toide K, Iwamoto Y, Fujiwara T, Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J Pharmacol Exp Ther. 1995 Sep;274(3):1370-8. PubMed PMID: 7562510.